Kan Yonemori
About
Kan Yonemori is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research.
According to data from OpenAlex, Kan Yonemori has authored 392 papers receiving a total of 6.2k indexed citations (citations by other indexed papers that have themselves been cited), including 246 papers in Oncology, 152 papers in Pulmonary and Respiratory Medicine and 72 papers in Cancer Research. Recurrent topics in Kan Yonemori's work include HER2/EGFR in Cancer Research (70 papers), Sarcoma Diagnosis and Treatment (59 papers) and Cancer Treatment and Pharmacology (45 papers). Kan Yonemori is often cited by papers focused on HER2/EGFR in Cancer Research (70 papers), Sarcoma Diagnosis and Treatment (59 papers) and Cancer Treatment and Pharmacology (45 papers). Kan Yonemori collaborates with scholars based in Japan, United States and United Kingdom. Kan Yonemori's co-authors include Yasuhiro Fujiwara, Kenji Tamura, Chikako Shimizu, Masashi Ando, Mayu Yunokawa, Noriyuki Katsumata, Makoto Kodaira, Tatsunori Shimoi, Akihiko Shimomura and Takayuki Kinoshita and has published in prestigious journals such as New England Journal of Medicine, Nature Medicine and Journal of Clinical Oncology.
In The Last Decade
Kan Yonemori
372 papers receiving 6.0k citations
Hit Papers
Peers
Kan Yonemori
Ashley E. Winkler United States
Dimosthenis Skarlos Greece
Shenghui Tang United States
Jee Hyun Kim South Korea
Marcia S. Brose United States
George Pentheroudakis Greece
Kyung-Hun Lee South Korea
Maria E. Cabanillas United States
Kimberly Blackwell United States
Lori J. Wirth United States
Citations per year, relative to Kan Yonemori Kan Yonemori (= 1×)
peers
Ashley E. Winkler
Countries citing papers authored by Kan Yonemori
Since
Specialization
Citations
This map shows the geographic impact of Kan Yonemori's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kan Yonemori with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kan Yonemori more than expected).
Fields of papers citing papers by Kan Yonemori
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Kan Yonemori. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kan Yonemori. The network helps show where Kan Yonemori may publish in the future.
Co-authorship network of co-authors of Kan Yonemori
This figure shows the co-authorship network connecting the top 25 collaborators of Kan Yonemori. A scholar is included among the top collaborators of Kan Yonemori based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kan Yonemori. Kan Yonemori is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Yoshida, Tatsuya, Kuniko Sunami, Takafumi Koyama, et al.. (2025). Upfront liquid biopsy in patients with advanced solid tumors who were not feasible for tissue-based next-generation sequencing. Japanese Journal of Clinical Oncology. 55(7). 720–728.
2.
Yonemori, Kan, Keiichi Fujiwara, Kosei Hasegawa, et al.. (2024). Analysis of East Asia subgroup in Study 309/KEYNOTE-775: lenvatinib plus pembrolizumab versus treatment of physician’s choice chemotherapy in patients with previously treated advanced or recurrent endometrial cancer. Journal of Gynecologic Oncology. 35(2). e40–e40.
3.
Hamilton, Erika, Sara A. Hurvitz, Seock‐Ah Im, et al.. (2024). Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): Updated survival results of DESTINY-Breast03.. Journal of Clinical Oncology. 42(16_suppl). 1025–1025.
4.
Nishikawa, Tadaaki, Hiroshi Yoshida, Kouya Shiraishi, et al.. (2024). Unveiling pembrolizumab effectiveness in diverse subtypes of MSI-high endometrial cancers. Journal of Gynecologic Oncology. 35(6). e103–e103.
5.
Curigliano, Giuseppe, Xichun Hu, Rebecca Dent, et al.. (2024). Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06).. Journal of Clinical Oncology. 42(17_suppl). LBA1000–LBA1000.
6.
Kogawa, Takahiro, Toshinari Yamashita, Takanori Ishida, et al.. (2024). Phase Ib trial of tasurgratinib (E7090) with or without endocrine therapies for patients (pts) with ER+, HER2− recurrent/metastatic breast cancer (BC) after receiving a CDK4/6 inhibitor.. Journal of Clinical Oncology. 42(16_suppl). 3103–3103.
7.
Ikeuchi, Hiroshi, Rika Kusumoto‐Matsuo, Shinya Kojima, et al.. (2024). GLI1 confers resistance to PARP inhibitors by activating the DNA damage repair pathway. Oncogene. 43(41). 3037–3048.
8.
Kawai, Akira, Tatsunori Shimoi, Eisuke Kobayashi, et al.. (2024). Histological diagnostic discrepancy and its clinical impact in bone and soft tissue tumors referred to a sarcoma center. Cancer Science. 115(8). 2831–2838.
9.
Kojima, Yuki, Emi Noguchi, Shigehiro Yagishita, et al.. (2023). Development of a Detection System for ESR1 Mutations in Circulating Tumour DNA Using PNA-LNA-Mediated PCR Clamping. Diagnostics. 13(12). 2040–2040.
10.
Koyama, Takafumi, Toshio Shimizu, Yuki Kojima, et al.. (2023). Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study. Cancer Discovery. 13(8). 1814–1825.
11.
Jhaveri, Komal, X. Cynthia, Elgene Lim, et al.. (2023). 383MO Imlunestrant with or without everolimus or alpelisib, in ER+, HER2- advanced breast cancer (aBC): Results from the phase Ia/b EMBER study. Annals of Oncology. 34. S338–S339.
12.
Oaknin, Ana, Funda Meric‐Bernstam, Joshua M. Lang, et al.. (2023). P-126 TROPION-PanTumor03, a phase 2, multicentre study of datopotamab deruxtecan (Dato-DXd) as monotherapy and in combination with anticancer agents in patients with advanced/metastatic solid tumours: Substudies in gastric and colorectal cancer. Annals of Oncology. 34. S59–S60.
13.
Colomba, Émeline, Domenica Lorusso, Helen Mackay, et al.. (2023). 748P Outcomes for patients (pts) with advanced endometrial cancer (aEC) who completed pembrolizumab (pembro) and continued lenvatinib (LEN) in the phase III Study 309/KEYNOTE-775. Annals of Oncology. 34. S512–S513.
14.
Okuma, Hitomi Sumiyoshi, Hiroshi Yoshida, Yoshihisa Kobayashi, et al.. (2023). Molecular pathology quality control in Southeast Asia: Results of a multiregional quality assurance study from MASTER KEY Asia. Cancer Science. 114(6). 2664–2673.
15.
Lorusso, Domenica, Vicky Makker, Antonio Casado, et al.. (2022). 2022-RA-653-ESGO The impact of histology, prior therapy, and dMMR status on lenvatinib + pembrolizumab outcomes in patients with advanced endometrial cancer: A subgroup analysis of Study 309/KEYNOTE-775. International Journal of Gynecological Cancer. 32. A102–A102.
16.
Kitano, Shigehisa, Yutaka Fujiwara, Toshio Shimizu, et al.. (2022). A feasibility study of lenvatinib plus pembrolizumab in Japanese patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 90(6). 523–529.
17.
Makise, Naohiro, Tatsunori Shimoi, Kuniko Sunami, et al.. (2022). Loss of H3K27 trimethylation in a distinct group of de‐differentiated chordoma of the skull base. Histopathology. 82(3). 420–430.
18.
Iwasa, Satoru, Takafumi Koyama, Makoto Nishino, et al.. (2022). First‐in‐human study of ONO ‐4578, an antagonist of prostaglandin E2 receptor 4, alone and with nivolumab in solid tumors. Cancer Science. 114(1). 211–220.
19.
Kojima, Yuki, Hiroshi Yoshida, Rui Kitadai, et al.. (2022). High expression of folate receptor alpha is associated with poor prognosis in patients with cervical cancer. Journal of Gynecologic Oncology. 33(6). e82–e82.
20.
Suzuki, Mikiko, Shigehiro Yagishita, Kiyoshi Sugihara, et al.. (2021). Visualization of Intratumor Pharmacokinetics of [fam-] Trastuzumab Deruxtecan (DS-8201a) in HER2 Heterogeneous Model Using Phosphor-integrated Dots Imaging Analysis. Clinical Cancer Research. 27(14). 3970–3979.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Ashley E. Winkler Breakdown of academic impact, for papers by Dimosthenis Skarlos Breakdown of academic impact, for papers by Shenghui Tang Breakdown of academic impact, for papers by Jee Hyun Kim Breakdown of academic impact, for papers by Marcia S. Brose Breakdown of academic impact, for papers by George Pentheroudakis Breakdown of academic impact, for papers by Kyung-Hun Lee Breakdown of academic impact, for papers by Maria E. Cabanillas Breakdown of academic impact, for papers by Kimberly Blackwell Breakdown of academic impact, for papers by Lori J. Wirth